# Contact Safe Semaglutide

> Contact Safe Semaglutide, an independent editorial digest of the peer-reviewed semaglutide literature. Editorial corrections and source suggestions welcome; no medical advice.

Corrections, citation suggestions and editorial questions — we read them all.

## Editorial contact

Safe Semaglutide is an independent editorial digest of the peer-reviewed semaglutide literature. If you have spotted an error, want to suggest a study we should summarize, or have a question about how we read a particular trial, the form below reaches the editorial desk. We especially welcome corrections — if a number or a citation here is wrong, we want to fix it.

What we cannot do is give medical advice. We are not a clinic, we have no clinicians on staff, and we cannot comment on whether semaglutide is right for you, what dose you should take, or how to manage a side effect. Those questions belong with a qualified clinician who knows your history. Please do not send personal health information.

## Send a message

Use the form to reach us. Helpful messages include a link or citation when you are flagging a factual point, so we can check it against the source quickly.

- **Name** — so we know how to address a reply.
- **Email** — so we can respond.
- **Message** — your correction, question, or suggested source.

We read every message and prioritize factual corrections to the cited record.

---

A documentation-grade reading room for the semaglutide trial record, read side by side with tirzepatide — every figure traced to the study that measured it; not a clinic, not a prescriber, and nothing here dosed, compounded, or sold.